Incidence and prognosis of thyroid cancer in children: based on the SEER database

Bing Zhang1 · Wenming Wu2,3 · Xiaofei Shang1 · Deliang Huang2,3 · Mingbo Liu2,3 · Liang Zong2,3

Accepted: 15 January 2022 / Published online: 29 January 2022
© The Author(s) 2022

Abstract
Objective To update the recognition of the trends in the incidence of childhood thyroid cancer (TC) and its prognosis.
Methods A large-scale sample based on long time-line public database was recruited. Join-point regression model was used to analyze the incidence trend of childhood TC. Univariable and multivariable Cox regression model analyses were applied to explore the survival situation and prognostic factors.
Results The incidence rate of childhood TC increased between 1975 and 2016 from 3.8/million (95% CI 2.6–5.5) to 11.5/million (95% CI 9.2–14.1), AAPC = 2.38% (95% CI 1.98–9.65) and could be divided into two stages of increasing trends. The incidence rate of Trend1 (1975–2005) increased slowly (APC = 1.08%, 95% CI 0.38–1.82) while Trend2 (2005–2016) increased dramatically (APC = 6.77%, 95% CI 4.30–9.28). Annual incidence rate of small size tumor (< 4 cm) and local stage childhood TC increased significantly. The overall cumulative survival rate for childhood TC was high up to 97–99%. Males, black race, MTC type, distant metastasis, tumor size ≥ 4 cm, non-primary cancer were the independent risk factors of childhood TC prognosis.
Conclusion A contribution of overdetection to rising pediatric TC rates might not be able to rule out. For clinical implications, screening TC in children with potential specific risk factors is feasible. Over-treatment to small size and local stage TC in children should be avoided.

Keywords Childhood thyroid cancer · Incidence trend · Join-point regression model · Prognosis factors

Introduction
Thyroid cancer (TC) is a common endocrine malignant tumor in both adults and children whose incidence has been increasing steadily for decades in the world [1, 2]. For example, TC incidence increased, on an average of 3.6% per year during 1974–2013 in the USA [3]. With improvements in diagnostic methods and implementation of advanced imaging modalities in the past decades, the diagnosis of micro-TC (< 1 cm) has been promoted, which would hardly cause symptoms or require treatment, explaining a substantial proportion of the increase of TC [3, 4].

Although TC is likely to be over-diagnosed among adults [5, 6], children are less frequent to receive thyroid screening or imaging examinations of the neck [7, 8]. Therefore, studying the incidence trend of childhood TC might better reflect the prevalence of this disease in the population. In addition, some types of childhood TC are more prone to have lymph node metastasis than in adults, with a wider range of lesions and leading a worse prognosis [9, 10]. Currently, many studies have reported the incidence and prevalence of TC in children and adolescents worldwide, with the age ranges from 0 to 20 years [11–13]. Most of the researches focus on exploring risk factors and the survival rate for childhood TC but pay less attentions to the prognosis factors on account of the very low mortality [14–18].

This study intended to update the recognition of the trends in the incidence of childhood TC and the prognosis factors through a large and public population-based cohort that are more time-span. First, the incidence of childhood...
TC was fitted using the join-point regression (JPR) model to explore its changing trend and its distribution in the population. Then, univariable and multivariable Cox regression model analyses were applied to explore the survival situation and prognostic factors of childhood TC. From epidemiological respect, we hope our study could provide more comprehensive acknowledgment for the prevalence and distribution of childhood TC. For clinical implications, we intended to provide constructive advice for clinical decision of TC in children.

**Materials and methods**

**Data resource**

Data in this study were attained from the Surveillance, Epidemiology, and End Results (SEER) program, one of the most representative databases of large oncology registries worldwide maintained by the United States government and its National Cancer Institute [19]. As an ongoing longitudinal program proceeding for decades, the SEER research reports annual national cancer statistics (approximately 10% of the United States cancer population) on incidence and survival and provides population data associated by age, sex, race, year of diagnosis, geographic areas, etc. on its website (https://seer.cancer.gov/data-software/), serving as a platform for offering systematic evidence to studies of cancer-related health disparities [20]. Information of childhood TC with age ranges from 0 to 19 years downloaded from “Incidence-SEER 18 Regs Custom Data (with additional treatment fields), Nov 2018 Sub (1975–2016)”.

TC patients were classified into histology subtypes based on the histology codes in the International Classification of Disease for Oncology, 3rd edition (ICD-O-3) SEER site/histology validation list 2015 [21], including differentiated TC (DTC) and undifferentiated TC (UTC). The histology subtypes are specifically identified using the following ICD-0-3 codes: Classic Papillary Thyroid Cancer (C-PTC): 8050/3, 8260/3, and 8343/3; Variant Papillary Thyroid Cancer (V-PTC): 8340/3, 8350/3, 8344/3, 8052/3, 8130/3, and 8342/3; FTC (Follicular Thyroid Cancer): 8330/3, 8331/3, 8332/3, and 8335/3; MTC (Medullary Thyroid Cancer): 8345/3, 8510/3, 8346/3, and 8347/3; and ATC (Anaplastic Thyroid Cancer): 8021/3 [21]. C-PTC, V-PTC, and FTC were classified as DTC while MTC and ATC were recognized as UTC. In this study, we collected types of C-PTC, V-PTC, FTC and MTC.

For cancer-directed surgery status, the “Subtotal or Near Total Thyroidectomy” and “Total Thyroidectomy” groups were combined to form “Total Thyroidectomy” group. The “Lobectomy” group consisted of TC patients who underwent lobectomy, with or without subsequent isthmusectomy. If a patient initially underwent a thyroid lobectomy and then went on to have a completion thyroidectomy, his/her surgery status in SEER was coded as “Total Thyroidectomy” [22].

In this study, we used the software SEER*Stat (version 8.3.9) to retrieve the complete TC cases with an age under 20 and a time span from 1975 to 2016 in the SEER database. A total of 4343 eligible patients were finally extracted according to pathologically confirmed diagnosis and integrated survival information. And annual standardized TC incidence rates were obtained. The following demographic and clinicopathological variables were included in our analysis: age, sex, race, histologic type, metastasis, radiation, chemotherapy, grade, surgery, AJCC stage, TNM stage, tumor size, primary cancer and survival information. Age groups were divided by 5 years per group. Due to the small number of patients aged 0–9 years, they were combined into one group. Race was aggregated into White, Black and others (American Indian/Alaskan Native or Asian/Pacific Islander). The primary outcomes in our study were overall survival (OS). OS was calculated as the time from diagnosis to death of TC.

**Join-point regression model**

The traditional regression analysis mainly reflects the overall trend of global data, but may not reveal the specific trend of local data. Therefore, the piecewise regression model comes into being [23]. The basic idea of the JPR model proposed by Kim et al. is to divide a long-term trend line into several statistically significant trend segments by model fitting, and each segment is described by continuous linearity, which could be linear data model or log-linear data model [24, 25]. Based on the annual incidence, this model mainly provides two outcome indicators: annual percent change (APC) and average annual percent change (AAPC) and corresponding confidence intervals (CIs). As a trend analysis of time series data, JPR model has been widely used in the field of epidemiological trends of cancer and chronic diseases, mainly to analyze the characteristics of temporal trends of morbidity and mortality [26–28].

**Statistical methods**

Summary statistics was used to describe the demographic characteristics and clinical data at baseline. The measurement data of normal distribution were described by means ± SD; the non-normal data were described by median and quartile range [M (Q1, Q3)]. Enumeration data were described by number of cases and composition ratio [N(%)]. Incidence rates were calculated per 100,000 persons and age-adjusted to the 2000 US Standard Population using SEER*Stat (version 8.3.9). The JPR model analysis was performed using Join-point Regression Program4.8 and trend
curves were presented using three-year rolling average for each calendar year. Survival analysis was performed with Cox proportional hazard regression model using R package survival. Kaplan–Meier (K–M) curve was used to show the survival curves. Log-rank test evaluated the statistically significant differences of survival. All other statistical analyses were performed using R4.0.2. Bilateral tests were used for all statistical tests. A value of \( P < 0.05 \) was considered statistically significant.

**Results**

**Demographics and incidence of childhood TC**

**Demographics of childhood TC**

A total of 4343 TC cases under 20 years old were included. Age 0–9 group consisted of 213 cases, accounting for 4.90% of the overall subjects; age 10–14 group consisted of 904 cases (20.82%); age 15–19 group consisted of 3,226 cases (74.28%). Male subjects were 824 cases accounted for 18.97% while female subjects were 3,519 cases accounted for 81.03%. Black race were 233 cases (5.23%), white race were 3,602 cases (84.44%), and other race were 441 cases (10.34%). The median follow-up time was 104.00 (Q1: 46.00, Q3: 193.00) months. The characteristics of demographics and clinic information at baseline are displayed in Table 1.

**Overall incidence of childhood TC**

Table 2 and Fig. 1 show the JPR analysis of trends in incidence. From 1975 to 2016, the overall incidence of childhood TC increased steadily, with age-standardized incidence rate (ASR) from 3.8/million (95% CI 2.6–5.5) to 11.5/million (95% CI 9.2–14.1), AAPC = 2.38% (95% CI 1.98–9.65). The incidence could be divided into two stages of trends. Trend1: between 1975 and 2005, the ASR of childhood TC increased slowly with APC = 1.08% (95% CI 0.38–1.82, \( P < 0.05 \)). Trend2: the ASR increased significantly from 2005 to 2016 with APC = 6.77% (95% CI 4.30–9.28, \( P < 0.001 \)). See Fig. 1A.

**Distribution of incidence of childhood TC**

We performed subgroup analyses of incidence by some interested population groups. Due to lack of data, the results of “0–9 years” group in “Race” and “< 1 cm” group in “Tumor size” were not applicable. From Table 2 and Fig. 1, the incidence of “10–14 years” group had no “join-point” and increased gradually from 1975 to 2016 (\( P < 0.05 \)) and so as “Male” group and “1–4 cm” (\( P < 0.05 \)). Differently, note that the incidence of “15–19 years” group, “Female” group, “White” group, “Differentiated” group and “Regional” group increased gradually from 1975 to 2005 (\( P < 0.05 \)) but sharply increased after 2005 (\( P < 0.05 \)), just as the tendency of overall incidence. Incidence trend of “Localized” group also suddenly increased after 2005 (\( P < 0.05 \)). Besides, the incidence of “Black”, “Distant” and “Undifferentiated” had no significantly increase (\( P > 0.05 \)).

**Risk factors for the prognosis of childhood TC**

**Univariable risk factors analysis**

Table 3 showed results of single risk factors analysis of prognosis in childhood TC. As shown in Table 3, there were no significant differences in risk of death between age groups. Male patients had 2.595 times of death risk compared to females (hazard ratio, HR 2.595, 95% CI 1.776–3.790). The black race patients had 3.029 times of death risk compared to the white race (HR 3.029, 95% CI 1.749–5.245).

In terms of clinic factors, due to mass of missing data (44–77%, see Table 1) of “grade”, “AJCC stage” and “TNM stage”, we are cautious of these results. And because very few subjects (19 cases, 0.44%) received chemotherapy, its result had bias. In “Histologic type” group, compared to “MTC”, other histologic types had lower death risk (\( P < 0.001 \)). The distant metastasis patients had much higher death risk compared to localized patients (HR 4.209, 95% CI 2.540–6.975). Patients who received lobectomy (HR 0.161, 95% CI 0.033–0.799) and total thyroidectomy (HR 0.279, 95% CI 0.087–0.899) had a reduced risk of death compared with those who did not undergo surgery. Patients who were “Primary cancer” had much lower death risk compared to those who were not (HR 0.186, 95% CI 0.106–0.325). Besides, whether received radiotherapy or not and tumor size had no significant difference for death risk in univariable analysis (\( P > 0.05 \)).

**Multivariate risk factors analysis**

Variables that were statistically significant in the univariable analysis, such as sex, race, histologic type, surgery type, metastasis and primary cancer, and common influencing factors like age and tumor size [21], were included in the multiple factors Cox regression model analysis. Finally, factors that were included in the regression model are presented in Table 4. Males (HR 2.659, 95% CI 1.524–4.641), black race (HR 2.345, 95% CI 1.027–5.399) and total thyroidectomy (HR 0.279, 95% CI 0.087–0.899) had a reduced risk of death compared with those who did not undergo surgery. Patients who were “Primary cancer” had much lower death risk compared to those who were not (HR 0.186, 95% CI 0.106–0.325). Besides, whether received radiotherapy or not and tumor size had no significant difference for death risk in univariable analysis (\( P > 0.05 \)).
Table 1 Characteristics of demographics and clinical information of childhood TC

| Variables                      | Total (n = 4343) | Alive (n = 4229) | Dead (n = 114) |
|--------------------------------|------------------|------------------|---------------|
| Age, n (%)                     |                  |                  |               |
| 00–09 years                    | 213 (4.90)       | 205 (4.85)       | 8 (7.02)      |
| 10–14 years                    | 904 (20.82)      | 877 (20.74)      | 27 (23.68)    |
| 15–19 years                    | 3226 (74.28)     | 3147 (74.41)     | 79 (69.30)    |
| Sex, n (%)                     |                  |                  |               |
| Female                         | 3519 (81.03)     | 3448 (81.53)     | 71 (62.28)    |
| Male                           | 824 (18.97)      | 781 (18.47)      | 43 (37.72)    |
| Race, n (%)                    |                  |                  |               |
| Black                          | 223 (5.23)       | 208 (5.01)       | 15 (13.16)    |
| White                          | 3602 (84.44)     | 3517 (84.71)     | 85 (74.56)    |
| Other                          | 441 (10.34)      | 427 (10.28)      | 14 (12.28)    |
| Histologic type, n (%)         |                  |                  |               |
| C-PTC                          | 2660 (63.32)     | 2601 (63.52)     | 59 (55.66)    |
| V-PTC                          | 1002 (23.85)     | 981 (23.96)      | 21 (19.81)    |
| FTC                            | 352 (8.38)       | 344 (8.40)       | 8 (7.55)      |
| MTC                            | 187 (4.45)       | 169 (4.13)       | 18 (16.98)    |
| Metastasis, n (%)              |                  |                  |               |
| Distant                        | 217 (5.12)       | 194 (4.69)       | 23 (21.30)    |
| Localized                      | 2062 (48.61)     | 2018 (48.81)     | 44 (40.74)    |
| Regional                       | 1963 (46.28)     | 1922 (46.49)     | 41 (37.96)    |
| Radiation, n (%)               |                  |                  |               |
| No                             | 1982 (45.64)     | 1923 (45.47)     | 59 (51.75)    |
| Yes                            | 2361 (54.36)     | 2306 (54.53)     | 55 (48.25)    |
| Chemotherapy, n (%)            |                  |                  |               |
| No                             | 4324 (99.56)     | 4214 (99.65)     | 110 (96.49)   |
| Yes                            | 19 (0.44)        | 15 (0.35)        | 4 (3.51)      |
| Grade, n (%)                   |                  |                  |               |
| I                              | 769 (17.71)      | 754 (17.83)      | 15 (13.16)    |
| II                             | 169 (3.89)       | 167 (3.95)       | 2 (1.75)      |
| III                            | 50 (1.15)        | 42 (0.99)        | 8 (7.02)      |
| IV                             | 10 (0.23)        | 8 (0.19)         | 2 (1.75)      |
| Unknown                        | 3345 (77.02)     | 3258 (77.04)     | 87 (76.32)    |
| Surgery, n (%)                 |                  |                  |               |
| No surgery                     | 59 (1.36)        | 56 (1.32)        | 3 (2.63)      |
| Lobectomy                      | 342 (7.87)       | 339 (8.02)       | 3 (2.63)      |
| Total thyroidectomy            | 3032 (69.81)     | 2988 (70.66)     | 44 (38.60)    |
| Unknown                        | 910 (20.95)      | 846 (20.00)      | 64 (56.14)    |
| AJCC stage, n (%)              |                  |                  |               |
| I                              | 2337 (53.81)     | 2316 (54.76)     | 21 (18.42)    |
| II                             | 70 (1.61)        | 69 (1.63)        | 1 (0.88)      |
| III and IV                     | 25 (0.58)        | 23 (0.54)        | 2 (1.75)      |
| Unknown                        | 1911 (44.00)     | 1821 (43.06)     | 90 (78.95)    |
| T stage, n (%)                 |                  |                  |               |
| T1                             | 998 (22.98)      | 990 (23.41)      | 8 (7.02)      |
| T2                             | 595 (13.70)      | 589 (13.93)      | 6 (5.26)      |
| T3                             | 699 (16.09)      | 695 (16.43)      | 4 (3.51)      |
| T4                             | 97 (2.23)        | 94 (2.22)        | 3 (2.63)      |
| Unknown                        | 1954 (44.99)     | 1861 (44.01)     | 93 (81.58)    |
| N stage, n (%)                 |                  |                  |               |
| NO                             | 1292 (29.75)     | 1278 (30.22)     | 14 (12.28)    |
| NI                             | 1151 (26.50)     | 1138 (26.91)     | 13 (11.40)    |
Table 1  (continued)

| Variables                    | Total (n = 4343) | Alive (n = 4229) | Dead (n = 114) |
|------------------------------|------------------|------------------|----------------|
| Unknown                      | 1900 (43.75)     | 1813 (42.87)     | 87 (76.32)     |
| **M stage, n (%)**           |                  |                  |                |
| M0                           | 2372 (54.62)     | 2349 (55.55)     | 23 (20.18)     |
| M1                           | 67 (1.54)        | 66 (1.56)        | 1 (0.88)       |
| Unknown                      | 1904 (43.84)     | 1814 (42.89)     | 90 (78.95)     |
| **Tumor size (cm), n (%)**   |                  |                  |                |
| < 1                          | 599 (13.79)      | 591 (13.97)      | 8 (7.02)       |
| 1– 9                         | 972 (22.38)      | 959 (22.68)      | 13 (11.40)     |
| 2– 14                        | 1423 (32.77)     | 1401 (33.13)     | 22 (19.30)     |
| ≥ 4                          | 726 (16.72)      | 707 (16.72)      | 19 (16.67)     |
| Unknown                      | 623 (14.34)      | 571 (13.50)      | 52 (45.61)     |
| **Primary cancer, n (%)**    |                  |                  |                |
| No                           | 123 (2.83)       | 109 (2.58)       | 14 (12.28)     |
| Yes                          | 4220 (97.17)     | 4120 (97.42)     | 100 (87.72)    |
| **Survival months, M (Q1,Q3)** | 104.0 (46.0,193.0) | 104.0 (46.0,192.0) | 97.5 (36.0,264.0) |

Some data are missing

Table 2  JPR analysis of trends in incidence of childhood TC

| Incidence     | Trend 1                      | Trend 2                      | AAPC 1975–2016 |
|---------------|------------------------------|------------------------------|----------------|
|               | Years                        | APC % (95% CI)               | Years          | APC % (95% CI)               |            |
| Overall       | 1975–2005                    | 1.08 (0.38–1.82)*            | 2005–2016      | 6.77 (4.30–9.28)*            | 2.38 (1.98–9.65)* |
| Ageb          | 00–09 years                  | NA                           | NA             | NA                           | NA          |
|               | 10–14 years                  | 2.25 (1.18–3.32)*            | 2.25 (1.18–3.32)* | 2.25 (1.18–3.32)*            | 2.25 (1.18–3.32)* |
|               | 15–19 years                  | 1.83 (0.82–2.92)*            | 2.98 (2.41–3.61)* | 2.98 (2.41–3.61)*            | 2.98 (2.41–3.61)* |
| Sex           | Female                       | 1.19 (0.41–2.00)*            | 2.43 (1.90–3.00)* | 2.43 (1.90–3.00)*            | 2.43 (1.90–3.00)* |
|               | Male                         | 2.19 (1.29–3.11)*            | 2.19 (1.29–3.11)* | 2.19 (1.29–3.11)*            | 2.19 (1.29–3.11)* |
| Race          | White                        | 1.37 (0.62–2.24)*            | 2.57 (2.01–3.12)* | 2.57 (2.01–3.12)*            | 2.57 (2.01–3.12)* |
|               | Black                        | 0.86 (0.42–2.12)             | 0.86 (0.42–2.12) | 0.86 (0.42–2.12)             | 0.86 (0.42–2.12) |
| Tumor size    | < 1                          | NA                           | NA             | NA                           | NA          |
|               | 1– 9                         | 4.09 (2.89–5.31)*            | 4.09 (2.89–5.31)* | 4.09 (2.89–5.31)*            | 4.09 (2.89–5.31)* |
|               | 2– 14                        | 2.22 (1.38–3.01)*            | 2.22 (1.38–3.01)* | 2.22 (1.38–3.01)*            | 2.22 (1.38–3.01)* |
|               | ≥ 4                          | − 1.1 (− 2.89–0.71)          | 4.78 (0.10–9.91)* | 0.58 (− 0.38–1.52)           | 0.58 (− 0.38–1.52) |
| Metastasis    | Localized                    | 0.57 (− 0.33–1.63)           | 5.00 (1.74–8.36)* | 2.13 (1.45–2.78)*           | 2.13 (1.45–2.78)* |
|               | Regional                     | 1.45 (0.56–2.34)*            | 7.95 (4.89–11.13)* | 3.03 (2.38–3.67)*           | 3.03 (2.38–3.67)* |
|               | Distant                      | 1.16 (− 2.13–4.56)           | 1.16 (− 2.13–4.56) | 1.16 (− 2.13–4.56)           | 1.16 (− 2.13–4.56) |
| Histologic type| Differentiated               | 1.27 (0.61–1.92)*            | 4.75 (1.78–7.82)* | 3.01 (2.52–3.54)*           | 3.01 (2.52–3.54)* |
|               | Undifferentiated             | 4.52 (12.10–24.31)           | 4.52 (12.10–24.31) | 4.52 (12.10–24.31)           | 4.52 (12.10–24.31) |

AAPC average annual percent change, APC annual percent change, NA not applicable (no sufficient data for analysis)

*The APC or AAPC is significantly different from zero (P < 0.05)
cancer (primary cancer, HR 0.089, 95% CI 0.043–0.185) were independent risk factors of the prognosis.

**K–M survival curves analysis**

K–M survival curves for the above independent risk factors as well as the overall survival are shown in Fig. 2, Log-rank test, see in Table S1. The overall cumulative survival rate for childhood TC from 1975 to 2005 was 97.70% and with a promotion to 99.27% from 2006 to 2016 \((P = 0.030)\). From 1975 to 2016, the survival rate for female was 97.98% and higher than that of male with 94.78% \((P < 0.001)\). The cumulative survival rate for race of white, black and other was 97.64%, 93.27% and 96.83%, respectively, and had a difference \((P < 0.001)\).

The cumulative survival rate for DTC was up to 98.88% and higher than that of UTC with 94.65% \((P < 0.001)\). The cumulative survival rate for tumor size \(< 4\) cm was around 99.15% and higher than that of size \(\geq 4\) cm with 97.80% \((P = 0.035)\). Cumulative survival rate for localized, regional and distant metastasis was 97.78%, 97.91% and 89.40% with a significant difference \((P < 0.001)\). The cumulative survival rate for primary cancer was 97.63% and much higher than that of non-primary cancer with 88.62% \((P < 0.001)\).

**Discussion**

The pattern of TC incidence in children and adolescents is similar to that in adults [29]. Compared to frequent over-diagnoses in TC among adults, children and adolescents are less likely to have over-detection effects from a clinical perspective [8, 11, 20, 30, 31]. Therefore, studying the incidence trend and exploring the prognostic factors of
### Table 3  Result of single risk factors analysis of prognosis of childhood TC

| Variables                  | β    | SE   | χ²  | P   | HR   | 95% CI  |
|----------------------------|------|------|-----|-----|------|---------|
|                            |      |      |     |     |      | Lower   |
|                            |      |      |     |     |      | Upper   |
| Age                        |      |      |     |     |      |         |
| 00–09 years                | Ref  |      |     |     |      |         |
| 10–14 years                | −0.169 | 0.403 | 0.177 | 0.674 | 0.844 | 0.383  |
| 15–19 years                | −0.398 | 0.371 | 1.150 | 0.284 | 0.672 | 0.325  |
| Sex                        |      |      |     |     |      |         |
| Female                     | Ref  |      |     |     |      |         |
| Male                       | 0.953 | 0.193 | 24.320 | <0.001 | 2.595 | 1.776  |
| Race                       |      |      |     |     |      |         |
| White                      | Ref  |      |     |     |      |         |
| Black                      | 1.108 | 0.280 | 15.645 | <0.001 | 3.029 | 1.749  |
| Other                      | 0.431 | 0.289 | 2.228 | 0.136 | 1.539 | 0.874  |
| Histologic type            |      |      |     |     |      |         |
| MTC                        | Ref  |      |     |     |      |         |
| C-PTC                      | −1.263 | 0.270 | 21.844 | <0.001 | 0.283 | 0.166  |
| V-PTC                      | −1.365 | 0.322 | 17.990 | <0.001 | 0.255 | 0.136  |
| FTC                        | −1.448 | 0.425 | 11.598 | <0.001 | 0.235 | 0.102  |
| Metastasis                 |      |      |     |     |      |         |
| Localized                  | Ref  |      |     |     |      |         |
| Regional                   | −0.011 | 0.217 | 0.002 | 0.961 | 0.989 | 0.647  |
| Distant                    | 1.437 | 0.258 | 31.109 | <0.001 | 4.209 | 2.540  |
| Radiotherapy               |      |      |     |     |      |         |
| Yes                        | Ref  |      |     |     |      |         |
| No                         | 0.143 | 0.194 | 0.543 | 0.461 | 1.153 | 0.789  |
| Chemotherapy               |      |      |     |     |      |         |
| Yes                        | Ref  |      |     |     |      |         |
| No                         | −1.989 | 0.511 | 15.153 | <0.001 | 0.137 | 0.050  |
| Grade                      |      |      |     |     |      |         |
| I                          | Ref  |      |     |     |      |         |
| II                         | −0.498 | 0.754 | 0.436 | 0.509 | 0.608 | 0.139  |
| III                        | 2.137 | 0.440 | 23.631 | <0.001 | 8.471 | 3.579  |
| IV                         | 2.519 | 0.760 | 10.999 | <0.001 | 12.418 | 2.802  |
| Surgery                    |      |      |     |     |      |         |
| No surgery                 | Ref  |      |     |     |      |         |
| Lobectomy                  | −1.825 | 0.817 | 4.993 | 0.025 | 0.161 | 0.033  |
| Total thyroidectomy        | −1.277 | 0.597 | 4.575 | 0.032 | 0.279 | 0.087  |
| AJCC stage                 |      |      |     |     |      |         |
| I                          | Ref  |      |     |     |      |         |
| II                         | 0.423 | 1.024 | 0.170 | 0.680 | 1.526 | 0.205  |
| III and IV                 | 2.333 | 0.745 | 9.793 | 0.002 | 10.305 | 2.391  |
| T stage                    |      |      |     |     |      |         |
| T1                         | Ref  |      |     |     |      |         |
| T2                         | 0.177 | 0.540 | 0.107 | 0.743 | 1.194 | 0.414  |
| T3                         | −0.319 | 0.612 | 0.272 | 0.602 | 0.727 | 0.219  |
| T4                         | 1.263 | 0.677 | 3.479 | 0.062 | 3.536 | 0.938  |
| N stage                    |      |      |     |     |      |         |
| N0                         | Ref  |      |     |     |      |         |
| N1                         | 0.082 | 0.385 | 0.045 | 0.832 | 1.085 | 0.510  |
| M stage                    |      |      |     |     |      |         |
| M0                         | Ref  |      |     |     |      |         |
childhood TC might better reflect the prevalence of this disease and offer useful clinical treatment suggestions. This study analyzed the trends in the incidence of childhood TC with distribution and explored the prognosis factors using JPR model and survival analysis, based on large samples with longitudinal data from the SEER database between 1975 and 2016.

The overall ASR of childhood TC increased from 3.8/ million (95% CI 2.6–5.5) to 11.5/million (95% CI 9.2–14.1) between 1975 and 2016, with AAPC = 2.38% (95% CI 1.98–9.65) and could be divided into two stages of increasing trends. Between 1975 and 2005 (Trend1), the incidence of childhood TC increased slowly (APC = 1.08%, 95% CI 0.38–1.82) while it had increased significantly

| Variables | $\beta$ | SE  | $\chi^2$ | $P$  | HR  | 95% CI Lower | 95% CI Upper |
|------------|--------|------|----------|------|-----|-------------|-------------|
| M1         | 0.383  | 1.022| 0.141    | 0.708| 1.467| 0.198       | 10.864      |
| Tumor size |        |      |          |      |     |             |             |
| < 1        |        |      |          |      |     |             |             |
| 1−         | − 0.100| 0.450| 0.050    | 0.823| 0.905| 0.375       | 2.183       |
| 2−         | − 0.070| 0.414| 0.028    | 0.866| 0.933| 0.415       | 2.098       |
| ≥ 4        | 0.446  | 0.423| 1.112    | 0.292| 1.562| 0.682       | 3.581       |
| Primary cancer |      |      |          |      |     |             |             |
| No         |        |      |          |      |     |             |             |
| Yes        | − 1.684| 0.286| 34.762   | <0.001| 0.186| 0.106       | 0.325       |

*The result had bias

| Variables | $\beta$ | SE  | $\chi^2$ | $P$  | HR  | 95% CI Lower | 95% CI Upper |
|------------|--------|------|----------|------|-----|-------------|-------------|
| Sex        |        |      |          |      |     |             |             |
| Female     |        |      |          |      |     |             |             |
| Male       | 0.978  | 0.284| 11.855   | <0.001| 2.659| 1.524       | 4.641       |
| Race       |        |      |          |      |     |             |             |
| White      |        |      |          |      |     |             |             |
| Black      | 0.852  | 0.421| 4.096    | 0.043| 2.345| 1.027       | 5.355       |
| Other      | − 0.176| 0.480| 0.134    | 0.714| 0.839| 0.327       | 2.149       |
| Histologic type |      |      |          |      |     |             |             |
| MTC        |        |      |          |      |     |             |             |
| C-PTC      | − 1.832| 0.406| 20.377   | <0.001| 0.160| 0.072       | 0.355       |
| V-PTC      | − 2.064| 0.476| 18.787   | <0.001| 0.127| 0.050       | 0.323       |
| FTC        | − 1.690| 0.590| 8.209    | 0.004| 0.185| 0.058       | 0.586       |
| Metastasis |        |      |          |      |     |             |             |
| Localized  |        |      |          |      |     |             |             |
| Regional   | 0.030  | 0.324| 0.008    | 0.927| 1.030| 0.546       | 1.944       |
| Distant    | 1.059  | 0.408| 6.736    | 0.009| 2.884| 1.296       | 6.419       |
| Tumor size |        |      |          |      |     |             |             |
| < 1        |        |      |          |      |     |             |             |
| 1−         | 0.604  | 0.517| 1.367    | 0.242| 1.829| 0.665       | 5.034       |
| 2−         | 0.731  | 0.486| 2.261    | 0.133| 2.076| 0.801       | 5.381       |
| ≥ 4        | 1.122  | 0.505| 4.933    | 0.026| 3.071| 1.141       | 8.264       |
| Primary cancer |      |      |          |      |     |             |             |
| No         |        |      |          |      |     |             |             |
| Yes        | − 2.421| 0.375| 41.716   | <0.001| 0.089| 0.043       | 0.185       |
Fig. 2  Factors affecting the grouping of KM curve (A Year, B Sex, C Race, D Tumor size, E Histologic subtype, F Extent of disease, G Primary lung cancer)
tion of incidence (Fig. 1), we found that the trends reported are consistent with prior findings. In the analysis of distributions of a previous study (2.4%, 4.6%, 4.3%, respectively) in 1988 and 2013. This incidence trend was similar to that of the present study during the same period (see Fig. 1A). Nevertheless, the advantage of this study is that we used a much longer timeline to observe the incidence trends of childhood TC, so that a fast-growing period was found (Trend2, since 2005).

The incidence of TC is known to vary widely according to age, gender, and race/ethnicity. Low in the first years of age, the incidence rates increase dramatically in adolescence, and are higher in girls than boys [2, 15, 18, 24]. This study is consistent with prior findings. In the analysis of distribution of incidence (Fig. 1), we found that the trends reported for overall incidence were largely driven by “15–19 years” group, “Female” group, “White” group, “Localized” group, “Regional” group and DTC types (papillary TC, 87%). Physiologically, this can be explained by differences in developmental status, hormone levels and race [2, 28, 32]. Besides, we observed that the annual increase rates of distant TC (1.16%) are lower than those observed for localized (2.13%) or regionally (3.03%), which was consistent with the findings of a previous study (2.4%, 4.6%, 4.3%, respectively) in adults TC [3].

Notably, the significant annual increases in the rates of small size tumor (< 4 cm) and local or regional stage TC in children since 2005 (Trend2) suggests that we might not be able to rule out a contribution of early detection (improvements in diagnostic methods) to rising pediatric DTC rates. A global study shows that there is over-diagnosis (improvements in diagnostic methods) to rising pediatric DTC, all sizes of tumor, localized, regional and primary cancer had a high cumulative survival rate above 97% while the cumulative survival rate of distant metastasis and non-primary cancer was lower than 90% (consistent with [18]) (Table S1). The overall high survival rate for childhood TC was consistent with previous studies [14–17]. Males, black race, distant metastasis, MTC subtype, tumors size ≥ 4 cm and non-primary cancer were the independent risk factors of prognosis in childhood TC. A study of analysis of prognosis in geriatric DTC showed that male, African American, tumors sized over than 4 cm, lymph node metastasis and distant metastasis, were strong risk factors in elderly DTC patients prognosis [34]. Prognostic factors of TC for children were similar to those for the elderly.

Current guidelines recommend total thyroidectomy and radio-ablation for most papillary thyroid cancer in children, which have been criticized as aggressive [35]. In this study, patients with lobectomy (HR 0.161, 95% CI 0.033–0.799) or total thyroidectomy (HR 0.279, 95% CI 0.087–0.899) had similar benefit in reduction of death in the univariable analysis. And radiotherapy had no impact for survival benefit. Similar result was reported in the study of [34]. No difference was found between lobectomy and total thyroidectomy with respect to DSS, and radiation therapy also conferred no apparent advantage. A study about total thyroidectomy vs. thyroid lobectomy for localized papillary TC in children also showed that both two methods had a good prognosis for children [35].

This study has its merits. First, this study is based on a large sample of public database which can provide reliable and powerful evidence. Many of the conclusions in this paper support those in the existing literature. Second, we used JPR model to analyze a long timeline database to observe the incidence trend of TC in children more comprehensively so that a fast-growing period was found. Some limitations need to be considered. First, the inherent limitations of the SEER dataset, such as the typical biases associated with a retrospective analysis and possible coding errors. Second, due to insufficient baseline information of the public database, we included limited potential risk factors into prognosis analysis. More additional potential factors including demographic characteristics, life behavior pattern, and clinical treatment information need to be considered in further researches.
Conclusion

Analysis based on SEER database revealed that the incidence rate of childhood TC increased between 1975 and 2016 and could be divided into two stages of increasing trends. The incidence rate of Trend1 (1975–2005) increased slowly but Trend2 (2005–2016) increased dramatically. A contribution of over-detection to rising pediatric TC rates might not be ruled out. The overall cumulative survival rate for childhood TC was high. Several risk factors of prognosis of childhood TC were identified. For clinical implications, screening TC in children with potential specific risk factors is feasible. Over-treatment to small size and local stage TC in children should be avoided. Still, additional potential prognosis factors including life behavior pattern, demographic characteristics and clinical treatment information need to be considered in further researches.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s00383-022-05069-3.

Acknowledgements We acknowledge all participants and staff in the collection of participants.

Author contributions Study conception and design: LZ. Data collection and clean: WW and XS. Real data analysis and interpretation: DH and ML. Drafting of the manuscript: BZ. All authors reviewed the manuscript.

Funding This study has no funding information.

Availability of data and material The datasets generated and/or analyzed during the current study are available in the [SEER] repository, [https://seer.cancer.gov/data-software/].

Declarations

Conflict of interest The authors declare that they have no competing interests.

Ethics approval and consent to participate The authors declare that there is no ethics problem.

Consent for publication Not applicable.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R (2013) Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol 2013:965212
2. Siegel DA, King J, Tai E, Buchanan N, Ajani UA, Li J (2014) Cancer incidence rates and trends among children and adolescents in the United States, 2001–2009. Pediatrics 134(4):e945–e955
3. Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM (2017) Trends in thyroid cancer incidence and mortality in the United States, 1974–2013. JAMA 317(13):1338–1348
4. Rossing M, Nygaard B, Nielsen FC, Bennedbaek FN (2012) High prevalence of papillary thyroid microcarcinoma in danish patients: a prospective study of 854 consecutive patients with a cold thyroid nodule undergoing fine-needle aspiration. Eur Thyroid J 1(2):110–117
5. Kent WD, Hall SF, Isoletao PA, Houlden RL, George RL, Groome PA (2007) Increased incidence of differentiated thyroid carcinoma and detection of subclinical disease. CMAJ 177(11):1357–1361
6. Vaccarella S, Franceschi S, Bray F, Wild CP, Plummer M, Dal Maso L (2016) Worldwide thyroid-cancer epidemic? The increasing impact of over-diagnosis. N Engl J Med 375(7):614–617
7. Niedziela M (2006) Pathogenesis, diagnosis and management of thyroid nodules in children. Endocr Relat Cancer 13(2):427–453
8. Gupta A, Ly S, Castronesve LA, Frates MC, Benson CB, Feldman HA et al (2014) How are childhood thyroid nodules discovered: opportunities for improving early detection. J Pediatr 164(3):658–660
9. Bendlova B, Sykorova V, Vaclavikova E, Vcelak J, Katra R, Sykorova P et al (2016) Thyroid cancer in children and adolescents and its molecular genetic background. Vnitr Lek 62(9 Suppl 3):40–44
10. Zeng X, Wang Z, Gui Z, Xiang J, Cao M, Sun W et al (2021) High incidence of distant metastasis is associated with histopathological subtype of pediatric papillary thyroid cancer—a retrospective analysis based on SEER. Front Endocrinol (Lausanne) 12:760901
11. Bernard MO, Withrow DR, de Gonzalez AB, Lam CJK, Linet MS, Kitahara CM et al (2019) Trends in pediatric thyroid cancer incidence in the United States, 1998–2013. Cancer 125(14):2497–2505
12. Liu S, Semenciw R, Ugnat AM, Mao Y (2001) Increasing thyroid cancer incidence in Canada, 1970–1996: time trends and age-period-cohort effects. Br J Cancer 85(9):1335–1339
13. Cho YY, Jang HW, Joung JY, Park SM, Jeong DJ, Kim SW et al (2015) Trends in thyroid cancer incidence in Korean children (1999–2012) based on palpation and nonpalpation detection methods. Eur Thyroid J 4(4):252–259
14. Stelianovaru-Foucher E, Stiller CA, Pukkala E, Lacour B, Plesko I, Parkin DM (2006) Thyroid cancer incidence and survival among European children and adolescents (1978–1997): report from the Automated Childhood Cancer Information System project. Eur J Cancer 42(13):2150–2169
15. Schmidt Jensen J, Gronhøj C, Mirian C, Jensen DH, Fribjerg J, Hahn CH et al (2018) Incidence and survival of thyroid cancer in children, adolescents, and young adults in Denmark: a nationwide study from 1980 to 2014. Thyroid 28(9):1128–1133
16. Silva F, Laguna R, Nieves-Rivera F (2010) Pediatric thyroid cancer: an update from the SEER database 2007–2012. Int J Pediatr Otorhinolaryngol 89:121–126
19. Liang W, He J, Shen Y, Shen J, He Q, Zhang J et al (2017) Impact of examined lymph node count on precise staging and long-term survival of resected non-small-cell lung cancer: a population study of the US SEER database and a Chinese Multi-Institutional Registry. J Clin Oncol 35(11):1162–1170

20. Noone AM, Lund JL, Mariotto A, Cronin K, McNeel T, Deapen D et al (2016) Comparison of SEER treatment data with medicare claims. Med Care 54(9):e55-64

21. Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69(1):7–34

22. Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA Cancer J Clin 70(1):7–30

23. Valsamis EM, Ricketts D, Husband H, Rogers BA (2019) Segmented linear regression models for assessing change in retrospective studies in healthcare. Comput Math Methods Med 2019:9810675

24. Kim HJ, Fay MP, Feuer EJ, Midthune DN (2000) Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 19(3):335–351

25. Li HZ, Du LB (2020) Application of Joinpoint regression model in cancer epidemiological time trend analysis. Zhonghua Yi Xue Za Zhi 54(8):908–912

26. Marshall DC, Webb TE, Hall RA, Salciccioli JD, Ali R, Maruthappu M (2016) Trends in UK regional cancer mortality 1991–2007. Br J Cancer 114(3):340–347

27. Lopez-Campos JL, Ruiz-Ramos M, Soriano JB (2014) Mortality trends in chronic obstructive pulmonary disease in Europe, 1994–2010: a joinpoint regression analysis. Lancet Respir Med 2(1):54–62

28. Nistal-Nuno B (2018) Joinpoint regression analysis to evaluate traffic public health policies by national temporal trends from 2000 to 2015. Int J Inj Contr Saf Promot 25(2):128–133

29. Vaccarella S, Lortet-Tieulent J, Colombet M, Davies L, Stiller CA, Schuz J et al (2021) Global patterns and trends in incidence and mortality of thyroid cancer in children and adolescents: a population-based study. Lancet Diabetes Endocrinol 9(3):144–152

30. Santin AP, Furlanetto TW (2011) Role of estrogen in thyroid function and growth regulation. J Thyroid Res 2011:875125

31. Li N, Du XL, Reitzel LR, Xu L, Sturgis EM (2013) Impact of enhanced detection on the increase in thyroid cancer incidence in the United States: review of incidence trends by socioeconomic status within the surveillance, epidemiology, and end results registry, 1980–2008. Thyroid 23(1):103–110

32. Yu B (2013) Predicting county-level cancer incidence rates and counts in the USA. Stat Med 32(22):3911–3925

33. Haymart MR, Reyes-Gastelum D, Caoli E, Norton EC, Banerjee M (2020) The relationship between imaging and thyroid cancer diagnosis and survival. Oncologist 25(9):765–771

34. Yu L, Hong H, Han J, Leng SX, Zhang H, Yan X (2020) Comparison of survival and risk factors of differentiated thyroid cancer in the geriatric population. Front Oncol 10:42

35. Memeh K, Ruhle B, Alsafran S, Vaghaiwalla T, Kaplan E, Angelos P et al (2021) Total thyroidectomy vs thyroid lobectomy for localized papillary thyroid cancer in children: a propensity-matched survival analysis. J Am Coll Surg 233(1):39–49

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.